Nuvalent Inc Reports Q3 2025 EPS Miss, Maintains Strong Cash Position for Future Growth

Nuvalent Inc reported a net loss of $122.4 million in Q3 2025, with increased R&D and G&A expenses. However, the company maintains a strong financial position with $943.1 million in cash and marketable securities, supporting future growth. Nuvalent is advancing several product candidates for non-small cell lung cancer and has completed a rolling NDA submission for zidesamtinib in ROS1-positive NSCLC. The company is also on track to report pivotal data for neladalkib in ALK-positive NSCLC by year-end.